Scarica l'app Stockscreener
78.21
2.60%
-2.09
Dopo l'orario di chiusura:
79.77
1.56
+1.99%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ILMN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$80.30
Aprire:
$80.3
Volume 24 ore:
3.76M
Relative Volume:
1.47
Capitalizzazione di mercato:
$12.09B
Reddito:
$4.34B
Utile/perdita netta:
$-965.00M
Rapporto P/E:
-12.88
EPS:
-6.07
Flusso di cassa netto:
$869.00M
1 W Prestazione:
+2.44%
1M Prestazione:
+4.20%
6M Prestazione:
-45.02%
1 anno Prestazione:
-32.33%
Intervallo 1D:
$77.50
$81.64
Intervallo di 1 settimana:
$75.24
$83.09
Portata 52W:
$68.70
$156.66
Illumina Inc Stock (ILMN) Company Profile
Nome
Illumina Inc
Settore
Industria
Telefono
(858) 202-4500
Indirizzo
5200 ILLUMINA WAY, SAN DIEGO, CA
Confronta ILMN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
78.21 | 12.09B | 4.34B | -965.00M | 869.00M | -6.07 |
|
TMO
Thermo Fisher Scientific Inc
|
406.05 | 153.96B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
187.82 | 138.19B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
509.42 | 39.13B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
111.52 | 30.65B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
141.82 | 26.52B | 15.50B | 1.33B | 2.16B | 7.34 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-04 | Reiterato | Citigroup | Neutral |
| 2025-02-28 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-02-10 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-02-07 | Downgrade | TD Cowen | Buy → Hold |
| 2024-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2024-11-12 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-10-17 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-08-28 | Aggiornamento | Argus | Hold → Buy |
| 2024-08-16 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2024-08-14 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2024-08-14 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-01-16 | Downgrade | HSBC Securities | Buy → Hold |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-14 | Iniziato | Stephens | Overweight |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-12-11 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-11-10 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | Iniziato | Bernstein | Underperform |
| 2023-07-05 | Ripresa | JP Morgan | Neutral |
| 2023-01-25 | Downgrade | Argus | Buy → Hold |
| 2023-01-05 | Iniziato | Scotiabank | Sector Perform |
| 2022-12-12 | Downgrade | Citigroup | Neutral → Sell |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-10-04 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2022-08-25 | Iniziato | Credit Suisse | Neutral |
| 2022-07-13 | Downgrade | Barclays | Equal Weight → Underweight |
| 2022-01-18 | Aggiornamento | Stifel | Hold → Buy |
| 2022-01-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-01-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2021-03-31 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | Iniziato | Barclays | Underweight |
| 2020-12-22 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-10-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-09-30 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | Downgrade | Stifel | Buy → Hold |
| 2020-09-22 | Downgrade | UBS | Buy → Neutral |
| 2020-09-21 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-09-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-08-07 | Downgrade | Evercore ISI | In-line → Underperform |
| 2020-08-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-04-24 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | Iniziato | Wells Fargo | Underweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-10-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Illumina Inc Borsa (ILMN) Ultime notizie
Illumina Inc (ILMN) CEO Jacob Thaysen Increases Stake with Recen - GuruFocus
Illumina Leadership to Share Strategic Vision at Prestigious Bernstein Conference May 28 - Stock Titan
Illumina unveils DRAGEN version 4.4 software focusing on oncology applications for clinical research - BioSpectrum India
Illumina, Inc. (ILMN): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey
South East Asia Molecular Diagnostics Market Forecast to 2031: PCR Technology Leads Growth, Kits & Reagents Hold Largest Share - GlobeNewswire Inc.
Onco-hematology Molecular Testing Market Top Players - openPR.com
Championing greater health in and outside the office - Illumina
NGS Library Preparation Market Growth Projections | Key Players: Illumina, Thermo Fisher Scientific, Roche - openPR.com
Illumina unveils DRAGEN v4.4 with enhanced accuracy - Investing.com
Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications - Illumina
Investing in Illumina (ILMN)? Don't Miss Assessing Its International Revenue Trends - Yahoo Finance
Illumina, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - simplywall.st
Illumina, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Yahoo Finance
Illumina Faces Uncertainties From China Ban, Research Slump, Morgan Stanley Says - marketscreener.com
Morgan Stanley Adjusts Illumina Price Target to $100 From $136, Maintains In Line Rating - marketscreener.com
Functional Genomics Market Top PlayersExact Sciences - openPR.com
Canaccord cuts Illumina stock target to $87, maintains hold By Investing.com - Investing.com India
Canaccord cuts Illumina stock target to $87, maintains hold - Investing.com
Illumina Q1 2025 revenue down 1% to USD 1.04 billion - Medical Buyer
Illumina outlines $4.18B to $4.26B guidance for 2025 amid China headwinds and strategic cost reductions - MSN
Illumina: Multiple Headwinds Point To Limited Upside In 2025 (NASDAQ:ILMN) - Seeking Alpha
Illumina (ILMN) Faces Adjusted Price Target and Positive Earnings Outlook | ILMN Stock News - GuruFocus
Illumina, Inc. (NASDAQ:ILMN) Q1 2025 Earnings Call Transcript - Insider Monkey
Cathie Wood’s ARK buys Shopify, Illumina stock; sells Palantir, Natera - Investing.com
Cathie Wood’s ARK buys Shopify, Illumina stock; sells Palantir, Natera By Investing.com - Investing.com India
Illumina (ILMN) Price Target Lowered by JP Morgan | ILMN Stock N - GuruFocus
SEC ends probe of Illumina’s Grail acquisition - MedTech Dive
TD Cowen raises Illumina stock target to $89, maintains Hold rating - Investing.com
Precision Medicine Market Analysis Report 2024-2030: Bristol-Myers Squibb, Illumina, Merck, AstraZeneca, and Roche Dominate with their Contributions to Research, Product Approvals, and Partnerships - GlobeNewswire
Illumina Q1 Earnings Top Estimates, Revenues Down Y/Y, Stock Dips - Yahoo Finance
Illumina Q1 2025 slides: Revises guidance downward amid China restrictions and tariff impacts - Investing.com
Lab-on-a-Chip Market Insights: Growth, Trends & Forecast - openPR.com
Illumina Inc (ILMN) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic ... By GuruFocus - Investing.com Canada
Earnings call transcript: Illumina Q1 2025 beats EPS forecast but faces stock dip - Investing.com
Illumina Reports Q1 2025 Financial Results Amid Challenges - TipRanks
Illumina: Q1 Earnings Snapshot - Norwalk Hour
Illumina (ILMN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Illumina confirms SEC has closed investigation into $8B Grail deal - Endpoints News
Illumina (ILMN) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
Illumina (ILMN) Shares Drop 3% Despite Beating Q1 EPS Estimates - GuruFocus
Illumina’s (NASDAQ:ILMN) Q1 Sales Top Estimates - Yahoo Finance
Illumina down 3% as lowered 2025 EPS guidance overshadows Q1 top-line beat - MSN
Illumina Cuts Guidance on Threat From Tariffs and China Ban - Bloomberg
Digital Genome Market Forecast: Growth Trends, Key Players & - openPR.com
Illumina Reports Financial Results for First Quarter of Fiscal Year 2025 - PR Newswire
Lobbying Update: $620,000 of ILLUMINA INC. lobbying was just disclosed - Nasdaq
Clinical Oncology Next-Generation Sequencing Market Size, - openPR.com
INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Illumina, Inc.(ILMN) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Single Cell Genome Sequencing Market Deep Research 2025-2032 | - openPR.com
ILLUMINA Earnings Preview: Recent $ILMN Insider Trading, Hedge Fund Activity, and More - Nasdaq
Here’s Why Artisan Mid Cap Fund Decided to Exit Illumina (ILMN) - Insider Monkey
Illumina Inc Azioni (ILMN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):